ロード中...
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma
Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete...
保存先:
| 出版年: | Blood Adv |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7422137/ https://ncbi.nlm.nih.gov/pubmed/32735654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002068 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|